Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of “Moderate Buy” from Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been given a consensus recommendation of “Moderate Buy” by the twenty-seven research firms that are currently covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $792.6522.

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Royal Bank Of Canada reduced their target price on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a report on Monday, May 18th. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research report on Monday, May 18th. Leerink Partners reaffirmed a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of REGN. WPG Advisers LLC grew its position in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $26,000. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $26,000. Titan Wealth CI Ltd purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $29,000. Finally, Board of the Pension Protection Fund purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $632.90 on Monday. Regeneron Pharmaceuticals has a 1-year low of $517.39 and a 1-year high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock’s 50-day moving average is $663.51 and its 200 day moving average is $728.45. The stock has a market cap of $66.91 billion, a price-to-earnings ratio of 15.42, a P/E/G ratio of 1.36 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the previous year, the business earned $8.22 earnings per share. The company’s quarterly revenue was up 19.0% on a year-over-year basis. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.